
Side Effects of Drugs Annual
A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
- 1st Edition, Volume 44 - November 23, 2022
- Editor: Sidhartha D. Ray
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 8 9 0 9 - 1
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 8 9 1 0 - 7
Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions, Volume 44, first published in 1977, presents clinicians and medical investiga… Read more

Purchase options

Institutional subscription on ScienceDirect
Request a sales quoteSide Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions, Volume 44, first published in 1977, presents clinicians and medical investigators with a critical survey of new data and trends in adverse drug reactions and interactions. Topics covered in this new release include Thyroid hormones, Iodine and Iodides, and Antithyroid Drugs, Side Effects of Antidepressant Medications, Side Effects of Lithium, Side Effects of Opioid Analgesics and Narcotic Antagonists, Side Effects of Beta-lactams and Tetracyclines, Side effects of Anti-diabetic Drugs, Vaccines, Side Effects of Neuromuscular Blockings Agents and Skeletal Muscle Relaxants, and much more.
Other chapters cover General Anesthetics and Therapeutic Gases, Drugs that Act on the Respiratory Tract, Positive Inotropic Drugs and Drugs Used in Dysrhythmias, Metals and Metal Antagonists, Antiseptic Drugs and Disinfectants with special scrutiny of COVID-19 pandemic related side effects, Drugs in tuberculosis and leprosy, Anthelminthic drugs, Blood and blood treatments, and a variety of other topics.
- Provides a critical yearly survey of the new data and trends regarding the side effects of drugs
- Authored and reviewed by worldwide pioneers in the clinical and practice sciences
- Presents an essential clinical guide on the side effects of drugs for practitioners and healthcare professionals alike
- Cover
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Special Reviews in SEDA 44
- Table of Essays, Annuals 1–43
- Abbreviations
- Focus on pharmacogenomics, phytonutrient–drug interactions and COVID-19 vaccines: Perspectives on ADRs, ADEs, and SEDs
- Introduction
- Pharmacogenomic considerations
- Immunological/hypersensitivity reactions
- Vaccine-induced adverse effects
- Analysis of toxicological reactions
- Phytonutrient–drug interactions
- Grades of adverse drug reactions
- FDA pregnancy categories/classification of teratogenicity
- References [Clinicians are suggested to be aware of the information contained in the following literature originating from regulatory agencies; Readers are advised to follow the most up-to-date info posted on respective websites prior to advising patients]
- Conclusion
- Chapter 1: Lithium
- Abstract
- Introduction
- Cardiovascular
- Nervous system
- Neuromuscular
- References
- Chapter 2: Antipsychotic agents
- Abstract
- Introduction
- FGAs
- SGAs
- Olanzapine
- Aripiprazole
- Risperidone
- Drug interaction
- Conclusion
- References
- Further reading
- Chapter 3: Drugs acting on the cerebral and peripheral circulations
- Abstract
- Drugs used in the treatment of migraines
- References
- Chapter 4: Side effects of antidepressants
- Abstract
- Introduction
- Antidepressant side effects
- References
- Chapter 5: Drugs of abuse
- Abstract
- Introduction
- Prescription drugs
- Illicit drugs
- Over the counter (OTC) drugs
- Other drugs
- Conclusion
- References
- Chapter 6: Side effects of drugs used in the treatment of Alzheimer's disease
- Abstract
- Introduction
- Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine)
- Aducanumab
- Memantine
- Conclusion
- References
- Chapter 7: Anti-epileptic medications
- Abstract
- Gamma-aminobutyric acid (GABA) receptor agonists (Aronson, 2016 [R]; Maroney & Markovic, 2021 [R]; Walker & Ray, 2020 [R]; Walker & Choi, 2019 [R])
- GABA reuptake inhibitors (Aronson, 2016 [R]; Maroney & Markovic, 2021 [R]; Walker & Ray, 2020 [R]; Walker and Choi, 2019 [R])
- GABA transaminase inhibitors (Aronson, 2016 [R]; Maroney & Markovic, 2021 [R]; Walker & Ray, 2020 [R]; Walker and Choi, 2019 [R])
- GABA analogues (Aronson, 2016 [R]; Maroney & Markovic, 2021 [R]; Walker & Ray, 2020 [R]; Walker and Choi, 2019 [R])
- Sodium Channel Blockers (Aronson, 2016 [R]; Maroney & Markovic, 2021 [R]; Walker & Ray, 2020 [R]; Walker & Choi, 2019 [R])
- Glutamate blockers (Aronson, 2016 [R]; Maroney & Markovic, 2021 [R]; Walker & Ray, 2020 [R]; Walker and Choi, 2019 [R])
- Miscellaneous other mechanisms of action (Aronson, 2016 [R]; Maroney & Markovic, 2021 [R]; Walker & Ray, 2020 [R]; Walker & Choi, 2019 [R])
- References
- Chapter 8: Antihypertensive drugs
- Abstract
- Introduction
- Special review: Skin cancer
- Angiotensin converting enzyme inhibitors [SEDA-39, 183–187; SEDA-40, 263; SEDA-41, 219–220; SEDA-42, 215–216; SEDA-43, 249–250]
- Angiotensin receptor blockers [SEDA-40, 263–264; SEDA-41, 220–221; SEDA-42, 216–218; SEDA-43, 250–251]
- Beta blockers [SEDA-40, 264–265; SEDA-41, 221–222; SEDA-42, 218–221; SEDA-43, 251–254]
- Calcium channel blockers [SEDA-40, 265; SEDA-41, 222–223; SEDA-42, 221–223; SEDA-43, 254–256]
- Diuretics [SEDA-41, 223–224; SEDA-42, 223–224; SEDA-43, 256–257]
- Alpha-2 agonists [SEDA-41, 224; SEDA-42, 224–225]
- Vasodilators [SEDA-41, 224–225; SEDA-42, 225]
- References
- Chapter 9: Positive inotropic drugs and drugs used in dysrhythmias
- Abstract
- Cardiac glycosides [SEDA-41, 183–194; SEDA-42, 183–193; SEDA-43, 207–209]
- Antidysrhythmic drugs
- References
- Chapter 10: Side effects of beta adrenergic antagonists and antianginal drugs
- Abstract
- Introduction
- Beta-adrenoreceptor antagonists [SEDA-41, 197; SEDA-42, 195; SEDA-43, 219]
- Bisoprolol
- Carvedilol
- Labetalol
- Metoprolol
- Nebivolol
- Propranolol
- Sotalol
- Timolol
- Calcium channel blockers [SEDA-41, 199; SEDA-42, 199; SEDA-43, 225]
- Amlodipine
- Diltiazem
- Nifedipine
- Verapamil
- Inhibitors of fatty acid oxidation [SEDA-42, 203; SEDA-43, 233]
- Trimetazidine
- Late sodium inhibitor [SEDA-41, 203 SEDA-42; 20]
- Nitrates [SEDA-43, 244]
- Potassium channel activators [SEDA-41, 202]
- References
- Chapter 11: Side effects of anti-lipid medications
- Abstract
- HMG-CoA reductase inhibitors
- PCSK9 inhibitors
- Bile acid sequestrant
- Fibric acid derivatives
- Omega-3 fatty acids/icosapent ethyl
- Niacin
- Bempedoic acid
- References
- Chapter 12: Side effects of opioid analgesics and narcotic antagonists
- Abstract
- Introduction
- Opioid full agonists [see Fig. 1; SEDA-24, 100; SEDA-26, 89; SEDA-39, 107; SEDA-41, 97; SEDA-42, 115]
- Partial agonists [see Fig. 2; SEDA-24, 100; SEDA-26, 89; SEDA-39, 107; SEDA-41, 97; SEDA-42, 115]
- Opioid antagonists [see Fig. 2; SEDA-24, 100; SEDA-26, 89; SEDA-39, 107; SEDA-41, 97; SEDA-42, 115]
- Conclusion
- References
- Chapter 13: Anti-inflammatory and antipyretic analgesics and drugs used in gout
- Abstract
- Aniline derivatives [SEDA-42, 12; SEDA-43, 135]
- Arylalkanoic acid derivatives [SEDA-42, 130; SEDA-43, 140]
- NSAID class effects
- Ketorolac [SEDA-42, 132; SEDA-43, 141]
- Propionic acid derivatives [SEDA-42, 132; SEDA-43, 142]
- Pyrazole derivatives [SEDA-42, 133; SEDA-43, 143]
- Drugs used in the treatment of gout [SEDA-42, 136; SEDA-43, 146]
- References
- Chapter 14: Neuromuscular blocking agents and skeletal muscle relaxants
- Abstract
- Introduction
- Depolarizing neuromuscular blocking agents
- Nondepolarizing neuromuscular blocking agents
- Neuromuscular blocker reversal agents
- Skeletal muscle relaxants
- References
- Chapter 15: General anaesthetics and therapeutic gases
- Abstract
- Dexmedetomidine
- Propofol
- Urinary tract
- Etomidate
- Ketamine
- Volatile agents
- Sevoflurane
- Liver
- Urinary tract
- Desflurane
- Nitrous oxide
- Methoxyflurane
- References
- Chapter 16: Side effects of local anesthetics
- Abstract
- Introduction
- Articaine
- Benzocaine
- Levobupivacaine
- Lidocaine
- Management of patients with allergy to local anesthetics: Two case reports
- Prilocaine
- Ropivacaine
- Combination drugs
- Special review
- Conclusion
- Acknowledgement
- References
- Further reading
- Chapter 17: Blood and blood treatments
- Abstract
- Introduction
- Chimeric antigen receptor
- Immunoglobulin
- Monoclonal antibodies
- Umbilical cord blood
- Thrombopoietin receptor agonist
- Glucocorticoid receptor agonist
- Anticoagulants
- Coagulation proteins
- Platelet-rich plasma
- References
- Chapter 18: Drugs that affect blood coagulation, fibrinolysis and hemostasis
- Abstract
- Warfarin and direct-acting anticoagulants
- Low molecular weight heparins (LMWH)
- Prothrombotic agents
- Anticoagulant reversal agents
- Thrombolytic agents
- References
- Chapter 19: Beta-lactams and tetracyclines
- Abstract
- Cephalosporins
- Penicillins
- Tetracyclines and glycylcyclines
- References
- Chapter 20: Side effects of miscellaneous antibacterial drugs
- Abstract
- Tetracyclines
- Lincosamides
- Macrolides
- Fluoroquinolones
- Glycopeptides
- Aminoglycosides
- Oxazolidinones
- Antibiotics, miscellaneous
- References
- Chapter 21: Antiviral drugs
- Abstract
- Drugs active against coronavirus disease 2019 (COVID-2019)
- Drugs active against cytomegalovirus (CMV)
- Drugs active against hepatitis B virus (HBV)
- Drugs active against hepatitis C virus (HCV)
- Drugs active against herpes simplex virus-1, -2 (HSV-1, HSV-2)
- Drugs active against human immunodeficiency virus (HIV): Integrase inhibitors (INSTIs)
- Drugs active against human immunodeficiency virus (HIV): Non-nucleoside reverse transcriptase inhibitors (NRTIs)
- Drugs active against human immunodeficiency virus (HIV): Nucleoside/-tide reverse transcriptase inhibitors (NNRTIs)
- Drugs active against human immunodeficiency virus (HIV): Protease inhibitors (PIs)
- Drugs active against influenza virus: Neuraminidase inhibitor
- Drugs active against influenza virus: Endonuclease inhibitor
- Conclusion
- References
- Chapter 22: Antifungal drugs
- Abstract
- Allylamines
- Azoles
- Echinocandins
- Polyenes
- Triterpenoid
- References
- Chapter 23: Drugs used in the treatment of tuberculosis and leprosy
- Abstract
- Introduction
- Organs and systems
- Aminoglycosides
- Bedaquiline
- Clofazimine
- Dapsone
- Delamanid
- Delpazolid
- Ethambutol
- Fluoroquinolones
- Isoniazid
- Linezolid
- Pretomanid
- Pyrazinamide
- Rifampicin
- Rifapentine
- References
- Chapter 24: Antihelminthic drugs
- Abstract
- Albendazole
- Diethylcarbamazine
- Ivermectin
- Levamisole
- Special review
- Mebendazole
- Moxidectin
- Praziquantel
- References
- Chapter 25: Vaccines
- Abstract
- Viral vaccines
- Parasitic vaccines
- Cross references
- References
- Further reading
- Chapter 26: Antiseptic drugs and disinfectants with experience of the second year of COVID-19 pandemic-related side effects
- Abstract
- Special review: COVID-19
- All commonly used antiseptics and disinfectants [SEDA-37, 273; SEDA-40, 289; SEDA-43, 276]
- Alcohols [SEDA-19, 235; SEDA-43, 279]
- Aldehydes [SEDA-39, 209; SEDA-40, 289; SEDA-41, 251; SEDA-42, 247; SEDA-43, 279]
- Guanidines
- Benzalkonium compounds [SEDA-39, 212; SEDA-40, 292; SEDA-41, 253; SEDA-42, 249; SEDA-43, 281]
- Triclosan [SEDA-37, 276; SEDA-39, 212; SEDA-40, 292; SEDA-41, 254; SEDA-42, 249]
- Ethylene oxide [SEDA-36, 341; SEDA-37, 273; SEDA-38, 214; SEDA-41, 254]
- Halogens
- Ultraviolet (UV) light [SEDA-43, 281]
- References
- Chapter 27: Side Effects of Gastrointestinal Drugs
- Abstract
- Acid-impacting agents
- Proton-pump inhibitors (PPIs) [SEDA-40, 463–466; SEDA-41, 408–412; SEDA-42, 362–366; SEDA-43, 415–419]
- Antidiarrheal and antispasmodic agents
- Antiemetic agents
- Prostaglandins
- Antiinflammatory agents
- Miscellaneous agents
- Biologics
- References
- Chapter 28: Side effects of insulin and oral antihyperglycemic drugs
- Abstract
- Introduction
- Insulin and associated adverse effects [Fig. 1; SEDA-40, 541; SEDA-41, 498; SEDA-42, 445; SEDA-43, 451]
- Oral antihyperglycemic drugs [see also Fig. 2] [SEDA-33, 894; SEDA-34, 688; SEDA-36, 648; SEDA-37, 526; SEDA-38, 454; SEDA-39, 435; SEDA-40, 540; SEDA-41, 496; SEDA-42, 443; SEDA-43, 451]
- Conclusion
- References
- Chapter 29: Drugs that act on the respiratory tract
- Abstract
- Leukotriene modifiers [SEDA-36, 245; SEDA-37, 197; SEDA-38, 160; SEDA-39, 166; SEDA-40, 219; SEDA-41, 172; SEDA-42, 172; SEDA-43, 197]
- Anticholinergic drugs [SEDA-36, 245; SEDA-37, 197; SEDA-38, 158; SEDA-39, 165; SEDA-40, 222; SEDA-41, 175; SEDA-42, 173; SEDA-43, 198]
- Anti-fibrotic therapies [SEDA-40, 224; SEDA-41, 177; SEDA-42, 175; SEDA-43, 199]
- Monoclonal antibodies [SEDA-38, 161; SEDA-39, 167; SEDA-40, 225; SEDA-41, 179; SEDA-42, 178; SEDA-43, 202]
- References
- Chapter 30: Metals and metal antagonists
- Abstract
- Ferroptosis
- Susceptibility factors
- Long term effects
- Susceptibility factors
- Long-term effects
- References
- Chapter 31: Side effects of anti-cancer medications
- Abstract
- DNA-crosslinking agents
- Antimetabolites
- Anti-microtubule agents
- Antibiotics
- Anti-HER2 antibodies
- Anti-VEGF and anti-VEGFR antibodies
- Tyrosine kinase inhibitors (TKIs)
- Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors
- Proteasome inhibitors
- Immune checkpoint inhibitors (ICIs)
- Multiple anti-cancer drugs
- References
- Chapter 32: Side effects, toxicity and ADRs of monoclonal antibodies in multiple organ systems
- Abstract
- Introduction
- Organ systems
- References
- Chapter 33: Thyroid hormones, iodine, and iodides, and antithyroid drugs
- Abstract
- Thyroid hormones (SEDA-42, 431–433; SEDA-43, 441–446)
- Thionamides (SEDA-42, 433–439; SEDA-43, 446–448)
- References
- Chapter 34: Drugs for metabolic bone disease
- Abstract
- Introduction
- Bisphosphonates
- Burosumab
- Calcitonin
- Denosumab
- Special review: Risks of denosumab discontinuation
- Romosozumab
- Parathyroid hormone and parathyroid hormone-related protein analogs
- References
- Chapter 35: Drugs used in ocular treatment
- Abstract
- Introduction
- Medications used to treat glaucoma
- Mydriatics
- Mydriatic reversing agents
- Anti-vascular endothelial growth factor (vegf) medications
- Anti-inflammatory agents
- Non-steroidal anti-inflammtory drugs (NSAIDs)
- Dry eye disease
- Anti-microbials
- Special review: Cenegermin
- Disclosure
- References
- Further reading
- Chapter 36: Vitamins, amino acids, nutrition, and complementary and alternative medicine
- Abstract
- Introduction
- Vitamin A [acitretin, alitretinoin, all-trans retinoic acid (atra), 13-cis retinoic acid (isotretinoin), carotenoids, etretinate] [SEDA-39, 345; SEDA-40, 431; SEDA-41, 387; SEDA-43, 513]
- Vitamins of the B group [SEDA-39, 346; SEDA-40, 433; SEDA-41, 390; SEDA-43, 518]
- Vitamin C (ascorbic acid) [SEDA-39, 349; SEDA-40, 435; SEDA-41, 392; SEDA-43, 519]
- Vitamin D analogues [SEDA-39, 349; SEDA-40, 436; SEDA-41, 393; SEDA-43, 519]
- Vitamin E (tocopherol) [SEDA-39, 351; SEDA-40, 439; SEDA-41, 394; SEDA-43, 521]
- Vitamin K analogues [SEDA-39, 352; SEDA-40, 439; SEDA-41, 394; SEDA-43, 521]
- Amino acids [SEDA-39, 352; SEDA-40, 440; SEDA-41, 394; SEDA-43, 522]
- Enternal nutrition [SEDA-39, 352; SEDA-40, 442; SEDA-41, 396; SEDA-43, 523]
- Parenteral nutrition [SEDA-39, 353; SEDA-40, 440; SEDA-41, 397; SEDA-43, 523]
- Complementary and alternative medicine [SEDA-40, 609; SEDA-41, 559; SEDA-42, 483; SEDA-43, 493]
- Conclusion
- Acknowledgement
- References
- Further reading
- Reviewers
- Index of Drugs
- Index of Drug-Drug Interactions
- Index of Adverse Effects and Adverse Reactions
- No. of pages: 584
- Language: English
- Edition: 1
- Volume: 44
- Published: November 23, 2022
- Imprint: Elsevier
- Hardback ISBN: 9780323989091
- eBook ISBN: 9780323989107
SR